2. Search Result
Search Result
Results for "

bystander effect

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128945
    CL2A

    		ADC Linker Inflammation/Immunology Cancer
    CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker .
    CL2A
  • HY-128945A
    CL2A TFA

    		ADC Linker Inflammation/Immunology Cancer
    CL2A TFA is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A TFA is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker .
    CL2A TFA
  • HY-128946
    CL2A-SN-38
    2 Publications Verification

    		 Drug-Linker Conjugates for ADC Inflammation/Immunology Cancer
    CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .
    CL2A-SN-38
  • HY-156513
    ZD06519

    7-Hydroxyethyl carbamate-(10Me-11F-Camptothecin)

    		 ADC Cytotoxin Cancer
    ZD06519 (7-Hydroxyethyl carbamate-(10Me-11F-Camptothecin)) is a camptothecin (HY-16560) analogue and a topoisomerase I inhibitor. ZD06519 is an ADC cytotoxin with a strong bystander effect, inhibiting a variety of malignancies such as HER2-positive and FRα-overexpressing tumors. ZD06519 inhibits DNA cleavage, relaxation, and reconnection processes, inducing tumor cell death. ZD06519 can be used for ADC synthesis and cancer research .
    ZD06519
  • HY-P99682
    Ladiratuzumab

    hLIV22

    		 ADC Antibody Cancer
    Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
    Ladiratuzumab